SLE assessments are designed to evaluate the diverse symptoms and impacts of lupus on individuals. Common assessments used in SLE research include:   BILAG (British Isles Lupus Assessment Group): An index used to assess disease activity, focusing on different organ systems. SLEDAI (Systemic Lupus Erythematosus Disease Activity Index): Measures disease activity in SLE by evaluating a combination of symptoms and laboratory results. CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): Specifically targets the assessment of skin-related symptoms in lupus patients. SLICC/ACR (Systemic Lupus International Collaborating Clinics/American College of Rheumatology): A damage index that evaluates the accumulated damage in various organ systems, not attributed to active lupus inflammation. Patient-Reported Outcomes(PROs): These are self-reported questionnaires that capture the patient's perspective on their symptoms, functional status, and well-being. The complexity of SLE often necessitates the use of several of these assessments in conjunction to provide a comprehensive view of the disease's activity, severity, and impact on the patient. Solutions like Clinical ink eLAS help in integrating these assessments and streamlining the process, enhancing the efficiency, and reliability of SLE trials.